Biogen Inc. ( BIIB ) and Boston Scientific ( BSX ) have both reported their earnings today, showcasing their recent first-quarter performances. Among their notable achievements are the remarkable success of Biogen's Alzheimer's drug Leqembi and Boston Scientific's strides in medical technology. Biogen Surpasses Expectations with Strong First-Quarter Performance Biogen Inc. surpassed market expectations for first-quarter profit, reporting adjusted earnings of $3.67 per share, outpacing analysts' forecasts of $3.44. The company's robust performance was buoyed by the growing traction of its new Alzheimer's drug, Leqembi, and significant cost-cutting measures. Shares of Biogen surged as much as 5.5% following the earnings announcement, marking the company's most substantial intraday gain since January 2023. The success of Leqembi, developed in collaboration with Japan's Eisai Co., is particularly notable. Sales of the Alzheimer's drug reached approxima